[Ip-health] Brazil Superior Court denies extension of Novartis Glivec/Gleevec patent

Joana Ramos jdr at ramoslink.info
Fri Oct 29 20:16:09 PDT 2010


**

http://www.thepharmaletter.com/file/99352/brazil-superior-court-denies-extension-of-novartis-glivecgleevec-patent.html**

26 October 2010

> Brazil Superior Court denies extension of Novartis Glivec/Gleevec patent
>
> Brazil's Third Chamber of the Superior Court of Justice (STJ) has 
> unanimously denied extending by almost a year the patent of Swiss drug 
> major Novartis' (NOVN: VX) imatinib (marketed as Gleevec in the USA 
> and Glivec in Europe and Latin America).
>
> Novartis maintains that its patent on imatinib is valid until March 
> 2013. However, the STJ confirmed the agreement of Brazil's 
> intellectual property agency, the INPI, that had granted the patent 
> until April 2012. ........
>
> **

*<snip>
*

*
> *Brazil spent some $153 million on Glivec in 2009
>
> According to a posting on the INPI's web site, in 2009, Brazil's 
> Department of Health spent about 260 million reals ($153.4 million) to 
> buy 8.5 million tablets of imatinib, at an average unit cost of 42.50 
> reals, and so the launch of a generic copy a year earlier than would 
> have been the case under Novartis' argument is expected to result in 
> significant cost savings for the Public Health System (SUS), which is 
> responsible for around 80% of the purchases of the branded drug.
> *
*

The above  the only mention I have so far found in English  on the 
decision.  Here is  link to one of many news article on the topic from 
Brazil;

http://www.clicrbs.com.br/diariocatarinense/jsp/default.jsp?uf=2&section=Geral&newsID=a3090471.htmDiário 
Catarinese
28/10/2010

> Decisão do STJ pode baratear medicamento para leucemia no Brasil, diz 
> Ministério da Saúde
> Medida passaria a valer em 2012..............
>
<snip>
> --- Com a quebra da patente aparecerão no mercado medicamentos 
> genéricos com essa substância e os preços cairão --- prevê Reinaldo 
> Guimarães.


Also is very interesting in view of the announcement by Novartis back in 
June-- which seems to have been reported  only in Brazil, although I my 
research has not been exhaustive) that it had made an agreemnt with the 
MS for signifciant price reductions on Glivec, over the next  2 years.


*http://tinyurl.com/24je6wp*
> Ministro anuncia no INCA redução do preço de remédio contra câncer
>
>  Jun 18, 2010 - O Ministro da Saúde, José Gomes Temporão, anunciou 
> nesta sexta-feira, 18/6, na reunião do Conselho Consultivo do INCA, 
> que o Ministério da Saúde conseguiu baixar em 51% o preço do 
> comprimido de Mesilato de Imatinibe (conhecido comercialmente como 
> Glivec) -- de R$ 42,50 para R$ 20,60,  gerando uma economia para o 
> Sistema Único de Saúde (SUS) de cerca de R$ 400 milhões em dois anos e 
> meio. Em 2011, Ministério centralizará a compra do medicamento e o 
> valor da unidade cairá ainda mais..........


And regarding this timely op-ed about José Serra's Bit Pharma ties:


http://www.vermelho.org.br/noticia.php?id_secao=1&id_noticia=140339

> Físico desmascara Serra sobre criação dos genéricos
> 28 de Outubro de 2010
>
> Nesse artigo "Genéricos e outros mistérios", Rogério Cezar de 
> Cerqueira Leite, físico e professor da Universidade Estadual de 
> Campinas (Unicamp), desmascara a propaganda do candidato José Serra 
> (PSDB) sobre a criação dos genéricos e o programa de combate a Aids. 
> Ele conta por que Serra foi escolhido "o homem do ano" pelo cartel de 
> multinacionais de medicamentos na época em que foi ministro da Saúde 
> do governo FHC........

With the  lucrative Glivec market share at stake,  likely there will be 
more patient relationship marketing efforts and other campaigns aimed at 
preserving Glivec brand  loyalty and questioning the efficacy of generics.

Joana
-----------------
Joana Ramos, MSW
Cancer Resources & Advocacy
Seattle WA USA
+1-206-229-2420
http://ramoslink.info/
www.bmtbasics.org
http://healthwatched.org





More information about the Ip-health mailing list